score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.K601E	0.1826	115.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.K601E (Missense)	1	DLBC_MUTECT2	TCGA-FA-8693-01A-11D-2397-10	TCGA-FA-8693-10A-01D-2397-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.Q22K	0.6103	272.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.Q22K (Missense)	1	DLBC_MUTECT2	TCGA-FA-A7Q1-01A-11D-A382-10	TCGA-FA-A7Q1-10A-01D-A385-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.L19F	0.2367	169.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.L19F (Missense)	1	DLBC_MUTECT2	TCGA-VB-A8QN-01A-11D-A382-10	TCGA-VB-A8QN-10A-01D-A385-10
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.A255T	0.3077	13.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.A255T (Missense)		DLBC_MUTECT2	TCGA-GR-A4D9-01B-11D-A31X-10	TCGA-GR-A4D9-10A-01D-A31X-10
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.V161I	0.3548	31.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.V161I (Missense)		DLBC_MUTECT2	TCGA-GS-A9TT-01A-11D-A382-10	TCGA-GS-A9TT-10A-01D-A385-10
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.R335*	0.1772	158.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.R335* (Nonsense)	1	DLBC_MUTECT2	TCGA-VB-A8QN-01A-11D-A382-10	TCGA-VB-A8QN-10A-01D-A385-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P1568Lfs*44	0.3086	81.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1568Lfs*44 (Frameshift)		DLBC_MUTECT2	TCGA-FA-A86F-01A-11D-A382-10	TCGA-FA-A86F-10A-01D-A385-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q200*	0.3235	34.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q200* (Nonsense)		DLBC_MUTECT2	TCGA-GS-A9TQ-01A-11D-A382-10	TCGA-GS-A9TQ-10A-01D-A385-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.W1670*	0.3902	41.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.W1670* (Nonsense)		DLBC_MUTECT2	TCGA-GR-A4D9-01B-11D-A31X-10	TCGA-GR-A4D9-10A-01D-A31X-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.S2581T	0.2632	114.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.S2581T (Missense)	1	DLBC_MUTECT2	TCGA-GR-A4D4-01A-11D-A31X-10	TCGA-GR-A4D4-10A-01D-A31X-10
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.R371C	0.2632	19.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.R371C (Missense)	0	DLBC_MUTECT2	TCGA-FA-A7Q1-01A-11D-A382-10	TCGA-FA-A7Q1-10A-01D-A385-10
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.M1192I	0.1724	116.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.M1192I (Missense)	0	DLBC_MUTECT2	TCGA-GS-A9TW-01A-11D-A382-10	TCGA-GS-A9TW-10A-01D-A385-10
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.A573V	0.5038	131.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.A573V (Missense)	0	DLBC_MUTECT2	TCGA-FF-8041-01A-11D-2210-10	TCGA-FF-8041-10A-01D-2210-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.A242E	0.2105	38.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.A242E (Missense)		DLBC_MUTECT2	TCGA-GS-A9TQ-01A-11D-A382-10	TCGA-GS-A9TQ-10A-01D-A385-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X332_splice	0.4167	60.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X332_splice (Splice Site)		DLBC_MUTECT2	TCGA-GR-A4D4-01A-11D-A31X-10	TCGA-GR-A4D4-10A-01D-A31X-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.6744	43.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		DLBC_MUTECT2	TCGA-RQ-AAAT-01A-11D-A38X-10	TCGA-RQ-AAAT-10A-01D-A38X-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273C	0.5091	55.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273C (Missense)		DLBC_MUTECT2	TCGA-FA-A82F-01A-11D-A382-10	TCGA-FA-A82F-10A-01D-A385-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.I232T	0.85	40.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.I232T (Missense)		DLBC_MUTECT2	TCGA-GS-A9TY-01A-11D-A38X-10	TCGA-GS-A9TY-10A-01D-A38X-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E171*	0.8889	72.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E171* (Nonsense)		DLBC_MUTECT2	TCGA-FF-8043-01A-11D-2210-10	TCGA-FF-8043-10A-01D-2210-10
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.V758L	0.1346	104.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.V758L (Missense)		DLBC_MUTECT2	TCGA-GS-A9TW-01A-11D-A382-10	TCGA-GS-A9TW-10A-01D-A385-10
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.A597T	0.0702	57.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.A597T (Missense)		DLBC_MUTECT2	TCGA-FF-8041-01A-11D-2210-10	TCGA-FF-8041-10A-01D-2210-10
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Frameshift	p.A1041Pfs*6	0.3409	132.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.A1041Pfs*6 (Frameshift)		DLBC_MUTECT2	TCGA-FF-8042-01A-11D-2210-10	TCGA-FF-8042-10A-01D-2210-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.E673K	0.1705	217.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.E673K (Missense)	1	DLBC_MUTECT2	TCGA-GS-A9TZ-01A-11D-A38X-10	TCGA-GS-A9TZ-10A-01D-A38X-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.S1434N	0.6	110.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.S1434N (Missense)	1	DLBC_MUTECT2	TCGA-GS-A9TY-01A-11D-A38X-10	TCGA-GS-A9TY-10A-01D-A38X-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Nonsense	p.S1473Efs*6	0.1047	86.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.S1473Efs*6 (Nonsense)	0	DLBC_MUTECT2	TCGA-FA-A7DS-01A-11D-A382-10	TCGA-FA-A7DS-10A-01D-A385-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.G1145S	0.1935	93.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.G1145S (Missense)	0	DLBC_MUTECT2	TCGA-GS-A9TZ-01A-11D-A38X-10	TCGA-GS-A9TZ-10A-01D-A38X-10
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P553L	0.3553	152.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P553L (Missense)	0	DLBC_MUTECT2	TCGA-GS-A9TZ-01A-11D-A38X-10	TCGA-GS-A9TZ-10A-01D-A38X-10
Investigate Actionability	FDA-Approved			Somatic Variant	FANCL	Missense	p.P43S	0.3279	122.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	FANCL p.P43S (Missense)	0	DLBC_MUTECT2	TCGA-GS-A9TW-01A-11D-A382-10	TCGA-GS-A9TW-10A-01D-A385-10
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.S315F	0.4429	70.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.S315F (Missense)		DLBC_MUTECT2	TCGA-FA-A7Q1-01A-11D-A382-10	TCGA-FA-A7Q1-10A-01D-A385-10
Investigate Actionability	Guideline			Somatic Variant	TET2	Frameshift	p.N1748Tfs*15	0.1735	98.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.N1748Tfs*15 (Frameshift)		DLBC_MUTECT2	TCGA-FA-8693-01A-11D-2397-10	TCGA-FA-8693-10A-01D-2397-10
Investigate Actionability	Guideline			Somatic Variant	TET2	Nonsense	p.K1438*	0.84	125.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.K1438* (Nonsense)		DLBC_MUTECT2	TCGA-FF-8061-01A-11D-2210-10	TCGA-FF-8061-10A-01D-2210-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.Y54C	0.5934	91.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y54C (Missense)		DLBC_MUTECT2	TCGA-GS-A9TY-01A-11D-A38X-10	TCGA-GS-A9TY-10A-01D-A38X-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.G1460A	0.3115	122.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G1460A (Missense)		DLBC_MUTECT2	TCGA-GR-A4D4-01A-11D-A31X-10	TCGA-GR-A4D4-10A-01D-A31X-10
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R966W	0.2292	48.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R966W (Missense)		DLBC_MUTECT2	TCGA-GS-A9TZ-01A-11D-A38X-10	TCGA-GS-A9TZ-10A-01D-A38X-10
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.N286I	0.0769	247.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.N286I (Missense)		DLBC_MUTECT2	TCGA-FF-8047-01A-11D-2210-10	TCGA-FF-8047-10A-01D-2210-10
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.K11N	0.64	25.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.K11N (Missense)		DLBC_MUTECT2	TCGA-FA-A7DS-01A-11D-A382-10	TCGA-FA-A7DS-10A-01D-A385-10
Investigate Actionability			Guideline	Somatic Variant	ETV6	Splice Site	p.X11_splice	0.6154	26.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.X11_splice (Splice Site)		DLBC_MUTECT2	TCGA-FA-A7DS-01A-11D-A382-10	TCGA-FA-A7DS-10A-01D-A385-10
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.G876S	0.0796	201.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.G876S (Missense)		DLBC_MUTECT2	TCGA-GS-A9TV-01A-11D-A382-10	TCGA-GS-A9TV-10A-01D-A385-10
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.W72C	0.3357	140.0	0.0	0.0																									FGFR2 p.W72C (Missense)		DLBC_MUTECT2	TCGA-GS-A9TZ-01A-11D-A38X-10	TCGA-GS-A9TZ-10A-01D-A38X-10
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P888L	0.1515	66.0	0.0	0.0																									COL1A1 p.P888L (Missense)		DLBC_MUTECT2	TCGA-GS-A9TZ-01A-11D-A38X-10	TCGA-GS-A9TZ-10A-01D-A38X-10
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P569S	0.249	526.0	0.0	0.0																									BRD4 p.P569S (Missense)		DLBC_MUTECT2	TCGA-GS-A9TZ-01A-11D-A38X-10	TCGA-GS-A9TZ-10A-01D-A38X-10
Biologically Relevant				Somatic Variant	RAF1	Missense	p.E478K	0.1975	81.0	0.0	0.0																									RAF1 p.E478K (Missense)		DLBC_MUTECT2	TCGA-FF-8042-01A-11D-2210-10	TCGA-FF-8042-10A-01D-2210-10
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.D98N	0.2211	95.0	0.0	0.0																									NTRK3 p.D98N (Missense)		DLBC_MUTECT2	TCGA-FF-8042-01A-11D-2210-10	TCGA-FF-8042-10A-01D-2210-10
Biologically Relevant				Somatic Variant	MTOR	Nonsense	p.W1633*	0.0875	80.0	0.0	0.0																									MTOR p.W1633* (Nonsense)		DLBC_MUTECT2	TCGA-GS-A9TW-01A-11D-A382-10	TCGA-GS-A9TW-10A-01D-A385-10
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.R230Q	0.4028	144.0	0.0	0.0																									ESRP1 p.R230Q (Missense)		DLBC_MUTECT2	TCGA-GS-A9TW-01A-11D-A382-10	TCGA-GS-A9TW-10A-01D-A385-10
Biologically Relevant				Somatic Variant	AURKB	Missense	p.C263S	0.3125	64.0	0.0	0.0																									AURKB p.C263S (Missense)		DLBC_MUTECT2	TCGA-VB-A8QN-01A-11D-A382-10	TCGA-VB-A8QN-10A-01D-A385-10
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.G100R	0.42	50.0	0.0	0.0																									RUNX1T1 p.G100R (Missense)		DLBC_MUTECT2	TCGA-GS-A9TY-01A-11D-A38X-10	TCGA-GS-A9TY-10A-01D-A38X-10
Biologically Relevant				Somatic Variant	MYC	Missense	p.S175N	0.2041	49.0	0.0	0.0																									MYC p.S175N (Missense)		DLBC_MUTECT2	TCGA-FA-A6HN-01A-11D-A31X-10	TCGA-FA-A6HN-10A-01D-A31X-10
Biologically Relevant				Somatic Variant	ROS1	Missense	p.L2051R	0.3077	26.0	0.0	0.0																									ROS1 p.L2051R (Missense)		DLBC_MUTECT2	TCGA-FF-A7CR-01A-11D-A382-10	TCGA-FF-A7CR-10A-01D-A385-10
Biologically Relevant				Somatic Variant	ERG	Missense	p.T139M	0.2759	87.0	0.0	0.0																									ERG p.T139M (Missense)		DLBC_MUTECT2	TCGA-FF-A7CR-01A-11D-A382-10	TCGA-FF-A7CR-10A-01D-A385-10
Biologically Relevant				Somatic Variant	CCND3	Missense	p.T283A	0.2239	67.0	0.0	0.0																									CCND3 p.T283A (Missense)		DLBC_MUTECT2	TCGA-GS-A9TU-01A-11D-A382-10	TCGA-GS-A9TU-10A-01D-A385-10
Biologically Relevant				Somatic Variant	CD274	Nonsense	p.W57*	0.12	125.0	0.0	0.0																									CD274 p.W57* (Nonsense)		DLBC_MUTECT2	TCGA-FA-8693-01A-11D-2397-10	TCGA-FA-8693-10A-01D-2397-10
Biologically Relevant				Somatic Variant	CD274	Missense	p.G159S	0.3083	120.0	0.0	0.0																									CD274 p.G159S (Missense)		DLBC_MUTECT2	TCGA-FA-8693-01A-11D-2397-10	TCGA-FA-8693-10A-01D-2397-10
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.H1962Pfs*2	0.2279	136.0	0.0	0.0																									NF1 p.H1962Pfs*2 (Frameshift)		DLBC_MUTECT2	TCGA-FA-8693-01A-11D-2397-10	TCGA-FA-8693-10A-01D-2397-10
Biologically Relevant				Somatic Variant	MYC	Missense	p.P245A	0.5	10.0	0.0	0.0																									MYC p.P245A (Missense)		DLBC_MUTECT2	TCGA-FF-8046-01A-11D-2210-10	TCGA-FF-8046-10A-01D-2210-10
Biologically Relevant				Somatic Variant	RAF1	Missense	p.T353I	0.2535	71.0	0.0	0.0																									RAF1 p.T353I (Missense)		DLBC_MUTECT2	TCGA-GS-A9TQ-01A-11D-A382-10	TCGA-GS-A9TQ-10A-01D-A385-10
Biologically Relevant				Somatic Variant	MYC	Missense	p.S169C	0.08	50.0	0.0	0.0																									MYC p.S169C (Missense)		DLBC_MUTECT2	TCGA-GS-A9TV-01A-11D-A382-10	TCGA-GS-A9TV-10A-01D-A385-10
Biologically Relevant				Somatic Variant	AURKB	Missense	p.V343A	0.1053	38.0	0.0	0.0																									AURKB p.V343A (Missense)		DLBC_MUTECT2	TCGA-FA-A4BB-01A-11D-A31X-10	TCGA-FA-A4BB-10A-01D-A31X-10
Biologically Relevant				Somatic Variant	NF1	Missense	p.N401K	0.0966	290.0	0.0	0.0																									NF1 p.N401K (Missense)		DLBC_MUTECT2	TCGA-FA-A4BB-01A-11D-A31X-10	TCGA-FA-A4BB-10A-01D-A31X-10
Biologically Relevant				Somatic Variant	ROS1	Missense	p.L968P	0.7711	83.0	0.0	0.0																									ROS1 p.L968P (Missense)		DLBC_MUTECT2	TCGA-GS-A9TT-01A-11D-A382-10	TCGA-GS-A9TT-10A-01D-A385-10
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.21																													COSMIC Signature (version 2) 1 (21%)		DLBC_MUTECT2		
Biologically Relevant				Mutational Signature	COSMIC Signature 6	version 2	0.337																													COSMIC Signature (version 2) 6 (34%)		DLBC_MUTECT2		
